Key result
Aspirin 500 mg significantly impaired thrombin formation in clotting blood, whereas placebo, indomethacin 50 mg, OKY-046 400 mg, and ticlopidine 500 mg had no effect.
Why the study?
Do antiplatelet drugs (aspirin, indomethacin, OKY-046, ticlopidine) reduce thrombin generation in healthy volunteers?
Population
Healthy volunteers
Comparison
Aspirin 500 mg, indomethacin 50 mg, OKY-046 400… vs Placebo
Design
Other
Follow-up
2 to 3 hours (up to 5 days for ticlopidine)
Authors
Loading...
May inform antiplatelet effects on thrombin; leaves open clinical translation pending patient studies.
Do antiplatelet drugs (aspirin, indomethacin, OKY-046, ticlopidine) reduce thrombin generation in healthy volunteers?
Aspirin, unlike other antiplatelet drugs tested, depresses thrombin formation in clotting blood, suggesting an additional mechanism of action via acetylation of prothrombin or platelet membrane macromolecules.
Szczeklik et al. (1992) studied Healthy volunteers. Aspirin, indomethacin, OKY-046, and ticlopidine vs. Placebo was evaluated on Thrombin formation (in vitro and ex vivo). Aspirin 500 mg significantly impaired thrombin formation in clotting blood, whereas placebo, indomethacin 50 mg, OKY-046 400 mg, and ticlopidine 500 mg had no effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: